Navigation Links
NCPA Statement on Wal-Mart's Entry Into the Pharmacy Benefit Market
Date:1/25/2008

ALEXANDRIA, Va., Jan. 25 /PRNewswire-USNewswire/ --- In a speech earlier this week, Wal-Mart Chief Executive Officer Lee Scott revealed the company was in the initial stages of offering pharmacy benefit manager services. In response Bruce Roberts, RPh, executive vice president and CEO of the National Community Pharmacists Association (NCPA) issued the following statement:

"The PBM industry badly needs to be reformed. The current PBM business model is one that lacks transparency and has come under fire in multiple legal proceedings such as when Medco Health Solutions agreed to pay the U.S. Government $155 million in December 2006 for alleged illegal behavior involving false claims and kickbacks. That is why NCPA has been at the forefront of pushing legislative solutions at the federal and state level to empower community pharmacies with the type of business negotiations rights that would shield patients from many of the unscrupulous PBM practices.

"Wal-Mart, a true corporate behemoth and the nation's third largest pharmacy retailer, has decided to become players in the PBM industry. They will have a dramatic affect on whether positive or negative changes occur. For example, PBMs are notorious for pushing patients to use the mail order pharmacies they actually own, which is a conflict of interest that is not to the patient's benefit. Another example of questionable PBM activities is the undue influence pharmaceutical manufacturers have in getting specific, often more expensive drugs utilized even when they are not part of the prescription plan formulary. This happens because of rebates the PBMs receive when these switches are successful. The list of dubious behavior by PBMs is extensive, but the common theme seems to be a relentless quest for profits regardless of what's in the best interest of patients.

"Wal-Mart has the opportunity to provide a positive influence on the PBM marketplace. Its pockets are deep and its sheer size causes
'/>"/>

SOURCE National Community Pharmacists Association
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Statement of Eli Lilly and Company on Dr. David Egilman Settlement:
2. Takeda statement on ACTOS meta-analysis published in the Journal of the American Medical Association
3. Takeda Statement on ACTOS(R) (Pioglitazone HCl) Meta-Analysis Published in the Journal of the American Medical Association
4. Statement by Mike Leavitt Secretary of Health and Human Services on the United States-China Bilateral Meetings on Food and Drug Safety
5. Statement by Oscar S. Wyatt, Jr.
6. Statement from Employment Policies Institute on Senator Hillary Clintons Health Care Plan
7. Pelosi Statement on Proposed Entitlement Task Force
8. Statement by Robert Greenstein, Executive Director of the Center on Budget and Policy Priorities, on the New Congressional SCHIP Agreement
9. Statement on House/Senate Agreement on SCHIP Legislation
10. Statement from the Alliance for Quality Nursing Home Care
11. Produce for Better Health Foundation Releases Statement on Study Saying Fruit & Vegetable Consumption Not Strongly Associated With Colon Cancer Risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2009)... -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) ... Phase 2b 003-A1 study, known as the 003 ... pre-treated relapsed and refractory multiple myeloma patients. These ... Symposium at the 51st annual meeting of the ... Enrollment in this trial is complete (n=269), and ...
(Date:12/6/2009)... study provides welcome news for patients with a common ... The condition is estimated to impact 62,000 Canadians and ... clot forms in a vein and restricts the flow ... the clot may detach from its point of origin ... a potentially fatal condition known as a pulmonary embolism. ...
(Date:12/6/2009)... of Belluck & Fox, LLP says dangerous substances such as asbestos ... ... New York, NY (PRWEB) December 6, 2009 -- As ... be alert to reports of recalls due to lead paint or ... to 230,000 children visit hospital emergency rooms each year due to ...
(Date:12/5/2009)... Cuts for a Cause ,, Why: ... other terminal illnesses affecting children. All proceeds from each hair ... Hospital. Guests will enjoy complimentary beverages and hors d,oeuvres, provided ... Falls Church for all guests. Hoa Lai, a DJ known ...
(Date:12/5/2009)... Dec. 5 Leukemia and myeloproliferative disorders are ... today at the 51st Annual Meeting of the ... options and improved diagnostic methods for patients suffering ... acute lymphoblastic leukemia, and myelofibrosis that are based ...
Breaking Medicine News(10 mins):Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 2Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 3Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 4Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 5Health News:New drug shows promise for those with clotting disorders: McMaster researcher 2Health News:Belluck & Fox Law Firm Urges Caution When Buying Toys This Holiday Season 2Health News:Belluck & Fox Law Firm Urges Caution When Buying Toys This Holiday Season 3Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 2Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 3Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 4Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 5Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 6Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 7Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 8Health News:Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders 9
... UNICEF have renewed their international partnership for children for another ... on HIV/AIDS 'Unite For Children, Unite Against AIDS'. ... children to enjoy healthy recreation and promote girls' education in ... the agreement. ,UNICEF's regional office for South Asia ...
... body that is responsible for approving NHS treatments has ... blocked the usage of an anti-cancer drug. ... treated with the drug Alimta, whose scientific name ... National Institute for Health and Clinical Excellence (NICE). ...
... Post, the department of health of Washington, D.C.//, on Tuesday is ... between 14years and 84years, to a test, to ... launching of the campaign, to be named “Come Together D.C. ... HIV Testing Day. ,Gregg Pane, the director of the. ...
... It has been reported that towards the end of last ... transplant//. ,Surgeons at Sydney's Royal Prince Alfred Hospital ... Myles of Cowra in central-eastern New South Wales. Leanne Myles ... failure of her liver, kidneys, and pancreas. ,She ...
... Mice lacking a gene for normal immune functioning found ... attacks //liver and spleen - a new study finds. ... a pathogen called Leishmania donovani, affects certain internal organs. ... quite often affected by this infectious disease through the ...
... department today advised people to take precautionary measures in view ... and jaundice during summer. // ,The people have ... minutes and wash raw vegetables and fruit thoroughly before eating, ... has also advised people to wash hands with soap after ...
Other Medicine News:Health News:Lack of STAT1 -an Immune Protein, Pack Liver Infection Cure 2Health News:Lack of STAT1 -an Immune Protein, Pack Liver Infection Cure 3
(Date:12/4/2009)... Technologies, Inc., a wholly-owned subsidiary of Volcano Corporation (Nasdaq: ... successful testing of a novel integrated light source architecture ... engine design raises the bar on imaging speed and ... OCT light sources. This approach to optical engines ...
(Date:12/4/2009)... Neal Shore and E. David Crawford presented results for ... secondary end points of biochemical recurrence rate in a ... injection) or monthly leuprolide in prostate cancer patients during ... who received FIRMAGON 240/80 mg/month had a recurrence rate ...
(Date:12/3/2009)... NEW YORK, Dec. 3 Guidepoint Global, LLC , ... their Sleep Apnea Tracker, a monthly longitudinal data release that ... Sleep Apnea market. ,, The Sleep Apnea Tracker captures ... sold in the United States from 15 different equipment providers ...
Breaking Medicine Technology:Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 2Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 3Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 4Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 5Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 2Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 3Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 4Leading Primary Research Firm Guidepoint Global Announces Launch of Sleep Apnea Tracker 2ZyGEM Releases Data Confirming Its prepGEM 28R 29 Bacteria Kit Is a Simple Universal Method for Extracting DNA from Different Bacteria Species 51198 1ZyGEM Releases Data Confirming Its prepGEM 28R 29 Bacteria Kit Is a Simple Universal Method for Extracting DNA from Different Bacteria Species 51198 2ZyGEM Releases Data Confirming Its prepGEM 28R 29 Bacteria Kit Is a Simple Universal Method for Extracting DNA from Different Bacteria Species 51198 3ZyGEM Releases Data Confirming Its prepGEM 28R 29 Bacteria Kit Is a Simple Universal Method for Extracting DNA from Different Bacteria Species 51198 4Life Spine 28R 29 Announces FDA Clearance of FS3 28TM 29 Minimally Invasive Spinal System 51196 1Harvest Technologies Announces Completion of Patient Enrollment in its 60 Patient Clinical Trial in India Using Autologous Adult Stem Cells to Treat P 12956 1Harvest Technologies Announces Completion of Patient Enrollment in its 60 Patient Clinical Trial in India Using Autologous Adult Stem Cells to Treat P 12956 2Harvest Technologies Announces Completion of Patient Enrollment in its 60 Patient Clinical Trial in India Using Autologous Adult Stem Cells to Treat P 12956 3
... medical and economic advantages of nifedipine,GITS therapy ... 28, 2007 – Two recently,published articles in ... that the use of the long-acting calcium ... additional,benefits beyond its blood pressure lowing effect. ...
... shows orally-delivered GLP-1 is able to stimulate ... --,Emisphere Technologies, Inc. reported today results of ... Christoph,Beglinger, M.D. Division of Gastroenterology and Hepatology,University ... of,the study with glucagon-like peptide-1 (7-36 amide) ...
Other Medicine Technology:Calcium Channel Blocker Adalat GITS Offer Additional Benefits 2Calcium Channel Blocker Adalat GITS Offer Additional Benefits 3Emisphere Technologies, Inc. Reports Clinical Data on Oral Delivery,of GLP-1 and PYY 2Emisphere Technologies, Inc. Reports Clinical Data on Oral Delivery,of GLP-1 and PYY 3Emisphere Technologies, Inc. Reports Clinical Data on Oral Delivery,of GLP-1 and PYY 4Emisphere Technologies, Inc. Reports Clinical Data on Oral Delivery,of GLP-1 and PYY 5
Boston Multivision design is manufactured in Boston ES material for early presbyope patients. Boston Multivision lens provides crisp, clear vision at near, intermediate, and far distances and excelle...
... stretcher. M-701 Stretcher has a standard ... 32 in., measured with a 2 ... high range, 28 in. to 35 ... can be supplied optionally. Vinyl upholstery ...
... vital dye, used in matured cataract surgery, ... tissue enables the surgeon to see ... of trypan blue combined with sodium chloride ... following intraocular injection into the anterior chamber ...
Unmatched versatility for hemostasis wherever needed. Can be applied to suit your needs....
Medicine Products: